Based on the absence of activity for AKT inhibitors in the PPTP/C models, the narrow range of adult cancer populations in which AKT inhibitors appear to have efficacy, and the low frequency of the primary predictive genomic biomarker in the pediatric population, there is limited rationale for developing an AKT inhibitor for pediatric cancers. This evidence concerns the gene AKT1 and cancer.